GAITHERSBURG, Md., Sept. 05, 2017 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in Citi’s 12th Annual Biotech Conference.
Conference details are as follows:
Date: Thursday, September 7, 2017
Location: Mandarin Oriental hotel, Boston, MA
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Director, Investor Relations ir@novavax.com 240-268-2000 Westwicke Partners John Woolford john.woolford@westwicke.com 443-213-0506 Media Russo Partners, LLC David Schull Maggie Beller david.schull@russopartnersllc.com maggie.beller@russopartnersllc.com 212-845-4271
